FDA announces framework for moving Plan B OTC
The FDA announced it is proceeding to work with Duramed, a subsidiary of Barr Pharmaceuticals, to resolve the remaining policy issues associated with the marketing of Plan B as an OTC contraceptive option. The agency and the sponsor will discuss the sponsor's proposed restricted distribution and risk management plan as part of the framework for potential approvability as a nonprescription product for women aged 18 and older.
FDA announces framework for moving Plan B OTC
The FDA announced it is proceeding to work with Duramed, a subsidiary of Barr Pharmaceuticals, to resolve the remaining policy issues associated with the marketing of Plan B as an OTC contraceptive option. The agency and the sponsor will discuss the sponsor's proposed restricted distribution and risk management plan as part of the framework for potential approvability as a nonprescription product for women aged 18 and older. The FDA issued a statement that said, "The agency hopes both sides are committed to working diligently through these issues so the process can be wrapped up in a matter of weeks." The FDA's announcement was made on July 31, the day before Andrew von Eschenbach's nomination hearing for the position of FDA commissioner.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
